Terlipressin in catecholamine-resistant septic shock patients

Shock

Volumn 22, Issue 4, 2004, Pages 314-319

  Leone, Marc ^a   Albanèse, Jacques ^a   Delmas, Anne ^a   Chaabane, Wajdi ^a   Garnier, Franck ^a   Martin, Claude ^a  

^a HÔPITAL NORD   (France)

Author keywords

Dopamine; Hypotension; Norepinephrine; Organ dysfunction; Severe sepsis; Terlipressin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CATECHOLAMINE; CREATININE; DOPAMINE; HYPERTENSIVE FACTOR; LACTIC ACID; NORADRENALIN; TERLIPRESSIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL OXYGEN TENSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FLUID THERAPY; HEART INDEX; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; HYPOTENSION; INFUSION; INTENSIVE CARE; KIDNEY FUNCTION; LABORATORY DIAGNOSIS; LACTATE BLOOD LEVEL; LIVER FUNCTION; LUNG FUNCTION; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MESENTERY BLOOD FLOW; MICTURITION; MULTIPLE ORGAN FAILURE; OPEN STUDY; OUTCOMES RESEARCH; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROTHROMBIN TIME; RESUSCITATION; SEPTIC SHOCK; SYSTEMIC VASCULAR RESISTANCE; THROMBOCYTOPENIA;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BLOOD PLATELETS; DRUG RESISTANCE; EPINEPHRINE; FEMALE; FRANCE; HEART RATE; HOSPITAL MORTALITY; HUMANS; HYPOTENSION; LACTIC ACID; LYSINE VASOPRESSIN; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NOREPINEPHRINE; OXYGEN CONSUMPTION; PROSPECTIVE STUDIES; SHOCK, SEPTIC; URODYNAMICS; VASOCONSTRICTOR AGENTS;

EID: 7944224614     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000136097.42048.bd     Document Type: Article

References (38)

1. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 23:588-595, 2001.
2. Ince C, Sinaasappel M: Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 27:1369-1377, 1999.
3. Vincent JL: Hemodynamic support in septic shock. Intens Care Med 27:80-92, 2001.
4. Ronco JJ, Fenwick JC, Tweeddale MG, Wiggs BR, Phang PT, Cooper DJ, Cunningham KF, Russell JA, Walley KR: Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and non septic humans. JAMA 270:1724-1730, 1993.
5. Martin C, Papazian L, Perrin G, Saux P, Gouin F: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 103:1826-1831, 1993.
6. Desjars P, Pinaud M, Potel G, Tasseau F, Touze MD: A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med 15:134-137, 1987.
7. Reinhart K, Sakka SG, Meier-Hellmann A: Haemodynamic management of a patient with septic shock. Eur J Anaesthesiol 17:6-17, 2000.
8. Schreuder WO, Schneider AJ, Groeneveld AB, Thijs LG: Effect of dopamine versus norepinephrine on hemodynamic in septic shock: emphasis on right ventricular performance. Chest 95:1282-1288, 1989.
9. Goncalves JA Jr, Hydo LJ, Baries PS: Factors influencing outcome of prolonged norepinephrine therapy for shock in critical surgical illness. Shock 10:231-236, 1998.
10. Asliz ME, Rackow EC: Septic shock. Lancet 351:1501-1505, 1998.
11. Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Baueur P: Comparison of norepinephrine and dobutamine to norepinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intens Care Med 23:282-287, 1997.
12. De Backer D, Creteur J, Silva E, Vincent JL: Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 6:1659-1667, 2003.
13. Reilly PM, Wilkins KB, Fuh KC, Haglund U, Bulkley GB: The mesenteric hemodynamic response to circulatory shock: an overview. Shock 15:329-343, 2001.
14. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S: Modification of alpha 1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 30:894-899, 2002.
15. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279-1282, 1997.
16. Dünser M, Luckner G, Mayr A, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR: The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 93:7-13, 2001.
17. Patel BM, Chittock DR, Russell JA, Walley KR: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576-582, 2002.
18. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine resistant septic shock. Lancet 359:1209-1210, 2002.
19. American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1658-1662, 1992.
20. Leone M, Boutiere-Albanese B, Valette S, Camoin-Jau L, Barrau K, Albanese J, Martin C, Dignat-George F: Cell adhesion molecules as a marker reflecting the reduction of endothelial activation induced by glucocorticoids. Shock 21:311-314, 2004.
21. Westphal M, Stubbe H, Sielenkämper AW, Borgulya R, Van Aken H, Ball C, Bone HG: Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intens Care Med 29:301-308, 2003.
22. Undesser KP, Hasser EM, Haywood JR, Johnson AK, Bishop VS: Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ Res 56:410-417, 1985.
23. Bellomo R, Di Giantomaso D: Noradrenaline and the kidney: friends or foes? Crit Care 5:294-298, 2001.
24. Hesselvik JF, Brodin B: Low-dose norepinephrine in patients with septic shock and oliguria: effects on afterload urine flow, and oxygen transport. Crit Care Med 17:179-180, 1989.
25. Meadows D, Edwards JD, Wilkins RG, Nightingale P: reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 16:663-666, 1988.
26. Martin C, Eon B, Saux P, Aknin P, Gouin F: Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 18:282-285, 1990.
27. Desjars P, Pinaud M, Bugnon D, Tasseau F: Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 18:1048-1049, 1990.
28. Redl-Wenzel EM, Armbruster C, Edelmann G, Fischl E, Kolacny M, Wechsler-Fordos A, Sporn P: The effects of norepinephrine on haemodynamics and renal function in severe septic shock states. Intens Care Med 19:151-154, 1993.
29. Bellomo R, Kellum JA, Winiewski SR, Pinsky MR: Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 159:1186-1192, 1999.
30. Cronin RE, De Torrente A, Miller PD, Bulger RE, Burke TJ, Schrier RW: Pathogenic mechanisms in nearly norepinephrine induced acute renal failure: functional and histological correlates of protection. Kidney Int 14:115-125, 1978.
31. Anderson WP, Korner PI, Selig SE: Mechanisms involved in the renal responses to intravenous and renal artery infusions of noradrenaline in conscious dogs. J Physiol 321:21-30, 1981.
32. Zhang H, Smail N, Cabral A, Cherkhaoui S, Peny MO, Vincent JL: Effects of norepinephrine on regional blood flow and oxygen extraction capabilities during endotoxemic shock. Am J Respir Crit Care Med 1555:1965-1971, 1997.
33. Schaer GL, Fink MP, Parillo JE: Norepinephrine alone versus norepinephrine plus low-dose dopamine: enhanced renal blood flow with combination pressor therapy. Crit Care Med 13:492-496, 1985.
34. Edwards RM, Trizna W, Kinter LB: Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 256:F274-F278, 1989.
35. Tuchschmidt J, Fried J, Swinney R, Sharma OP: Early hemodynamic correlates of survival in patients with septic shock. Crit Care Med 17:719-723, 1989.
36. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS: Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 94:1176-1186, 1988.
37. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intens Care Med 30:536-555, 2004.
38. Opal SM: Clinical trial design and outcomes in patients with severe sepsis. Shock 20:295-302, 2003.